Alan Parsa, MD
Endocrinology, Diabetes & Metabolism · Honolulu, HINPI 1215268362
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $474,710 of the $584,337 with a category attached, or 81.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.4%. 2025 is the largest year on record at $157,284, 2.2 times the $72,408 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,433 payments — averaging $407.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$137K
- Novo Nordisk$136K
- Corcept Therapeutics$101K
- Boehringer Ingelheim$88K
- AstraZeneca$38K
- Abbott$37K
- plus $47K from 25 others
Across 99 payments — averaging $37,458 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.3M
- AbbVie$149K
- Dexcom, Inc.$140K
- Bayer$88K
What the payments were for
- Consulting fees$15,8503%
- Speaking & faculty fees$474,71081%
- Travel & lodging$48,3388%
- Food & beverage$45,3518%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 250 | $136,767 |
| Novo Nordisk | 271 | $136,029 |
| Corcept Therapeutics | 91 | $101,180 |
| Boehringer Ingelheim | 258 | $88,133 |
| AstraZeneca | 123 | $37,614 |
| Abbott | 94 | $37,139 |
| Dexcom, Inc. | 13 | $17,077 |
| Eli Lilly | 66 | $17,018 |
| Amgen(2 entities) | 64 | $7,561 |
| Bayer | 65 | $2,690 |
| Sanofi-aventis U.S. LLC | 40 | $702 |
| Radius Health, Inc. | 18 | $436 |
| Insulet Corporation | 23 | $387 |
| Tandem Diabetes Care, Inc. | 6 | $342 |
| Merck | 20 | $246 |
| Amarin Pharma, Inc. | 6 | $189 |
| Amryt Pharma Holdings Ltd | 3 | $181 |
| Neurocrine Biosciences, Inc. | 1 | $160 |
| AbbVie | 3 | $68 |
| Johnson & Johnson | 3 | $50 |
| Insmed, Inc. | 1 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $49 |
| Bioventus LLC | 2 | $41 |
| Senseonics, Incorporated | 1 | $41 |
| Recordati_rare_diseases_inc. | 2 | $38 |
| Medtronic | 2 | $38 |
| Averitas Pharma Inc. | 1 | $36 |
| Mannkind Corporation | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Vistapharm, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$112,292
- Korlym$99,968
- TRULICITY$66,823
- RYBELSUS$59,291
- Ozempic$57,654
- FARXIGA$34,603
- MOUNJARO$31,757
- FREESTYLE LIBRE 3$26,181
- DEXCOM G7 GSS (161)$16,833
- DEXCOM STELO GLUCOSE BIOSENSOR$16,833
- EVENITY$6,223
- FreeStyle Libre 2$6,075
- FreeStyle Libre Pro$3,375
- Kerendia$1,596
- FreeStyle Libre$450
- Saxenda$225
- TEPEZZA$179
- CRENESSITY$160
- t:slim X2 Insulin Pump with Control-IQ$148
- XIGDUO$125
How this compares
$584,337 in reported general payments places this provider in the 95th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
See all endocrinology, diabetes & metabolism providers in Hawaii →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 376 | $860,780 |
| TrulicityDulaglutide | 176 | $401,682 |
| JardianceEmpagliflozin | 246 | $362,498 |
| KorlymMifepristone | 11 | $231,019 |
| FarxigaDapagliflozin Propanediol | 145 | $216,868 |
| MounjaroTirzepatide | 78 | $176,326 |
| ForteoTeriparatide | 35 | $145,474 |
| RybelsusSemaglutide | 75 | $99,929 |
| TymlosAbaloparatide | 33 | $92,939 |
| Teriparatide | 40 | $80,524 |
| Tresiba Flextouch U-100Insulin Degludec | 110 | $70,424 |
| JanuviaSitagliptin Phosphate | 60 | $64,847 |
| KerendiaFinerenone | 37 | $62,929 |
| Victoza 3-PakLiraglutide | 21 | $41,276 |
| ProliaDenosumab | 23 | $41,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $136,029 | $967,277475 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo | $136,767 | $723,482289 claims |
| Boehringer IngelheimJardiance, Tradjenta | $88,133 | $403,029283 claims |
| Corcept TherapeuticsKorlym | $101,180 | $231,01911 claims |
| AstraZenecaFarxiga | $37,614 | $216,868145 claims |
| Radius Health, Inc.Tymlos | $436 | $92,93933 claims |
| AmgenProlia, Evenity (2 Syringes) | $7,561 | $69,82335 claims |
| MerckJanuvia | $246 | $64,84760 claims |
| BayerKerendia | $2,690 | $62,92937 claims |
| AbbVieSynthroid | $68 | $2,36047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
Other endocrinology, diabetes & metabolism in Honolulu
- Cindy PauHonolulu$13K
- Anna Melissa LoHonolulu$13K
- Lisa WongHonolulu$12K
- Eric LeeHonolulu$3K
- Isabel CasimiroHonolulu$2K
- Se Mo SuhHonolulu$2K
- Chanhaeng RheeHonolulu$2K
- Kamonkiat WirunsawanyaHonolulu$1K
- Jennifer LohHonolulu$890
- Lara WongHonolulu$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.